Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase 1 1

Status

Completed 5

Sponsor Class

INDUSTRY 5OTHER 4

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Carcinoma, Non-Small-Cell Lung 687Breast Neoplasms 585Neoplasms 468Colorectal Neoplasms 300Prostatic Neoplasms 263Neoplasm Metastasis 257Melanoma 242Ovarian Neoplasms 228Recurrence 216Lung Neoplasms 203Multiple Myeloma 196Lymphoma, Non-Hodgkin 155Pancreatic Neoplasms 154Leukemia, Myeloid, Acute 142Carcinoma, Hepatocellular 141Stomach Neoplasms 137Lymphoma 131Carcinoma, Renal Cell 128Glioblastoma 118Squamous Cell Carcinoma of Head and Neck 113Head and Neck Neoplasms 113Lymphoma, Follicular 106Leukemia, Lymphocytic, Chronic, B-Cell 99Small Cell Lung Carcinoma 96Lymphoma, Large B-Cell, Diffuse 96Leukemia 96Brain Neoplasms 91Carcinoma 82Uterine Cervical Neoplasms 77Triple Negative Breast Neoplasms 73

Interventions

MK-4721 2Gemcitabine 2Paclitaxel 1Ocoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Pancreatic Diseases × Clear all
NCT03077685 2024-06-24

Trial of NanoPacĀ® in Subjects With Locally Advanced Pancreatic Adenocarcinoma

NanOlogy, LLC

Phase 2 Completed
54 enrolled 17 charts
Gastrointestinal

Digestive System Diseases, Digestive System Neoplasms, Pancreatic Diseases, Pancreatic Neoplasms

NCT03717298 2023-03-28

Evaluation of Ocoxin-ViusidĀ® in Advanced Pancreatic Adenocarcinoma

Catalysis SL

Phase 2 Completed
30 enrolled
Gastrointestinal

Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Pancreatic Diseases, Pancreatic Neoplasms

NCT03188991 2021-06-14

Intracystic Injection of NanoPacĀ® in Subjects With Mucinous Cystic Pancreatic Neoplasms

NanOlogy, LLC

Phase 2 Completed
20 enrolled 13 charts
Gastrointestinal

Digestive System Neoplasms, Pancreatic Cyst, Pancreatic Diseases, Pancreatic Neoplasms

NCT01608711 2017-05-16

A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002

Astellas Pharma Inc

Phase 2 Completed
2 enrolled
Gastrointestinal

Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

NCT00902291 2015-09-14

A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer

Astellas Pharma Inc

Phase 2 Completed
205 enrolled
Gastrointestinal

Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon ⚔